Divi's Laboratories faces a ₹570 crore draft tax assessment for FY23, citing Transfer Pricing and corporate tax adjustments.

Divi’s Laboratories has received a draft tax assessment order proposing ₹570.51 crore in additions to FY23 income due to transfer pricing and corporate tax adjustments, with potential tax liability ...

Discover the Divis Labs Stock Liveblog, your go-to destination for real-time updates and comprehensive analysis of a ...

Join us on the Divis Labs Stock Liveblog, your hub for real-time updates and comprehensive analysis on a prominent stock.

Reported Consolidated quarterly numbers for Divis Laboratories are: Net Sales at Rs 2,604.00 crore in December 2025 up 12.29% ...

Divi’s Labs could emerge as a key beneficiary of the global GLP-1 drug boom, with new peptide manufacturing contracts and ...

India, March 12 -- Broking Jefferies is still optimistic about Divi's Laboratories and has stated that the company is set to ...

HYDERABAD, Aug 14 (Reuters) - Indian pharmaceutical company Divi's Laboratories (DIVI.NS), opens new tab reported a 49.2% fall in quarterly profit, missing analysts' estimates, as the generic drug ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey BENGALURU (Reuters) - Shares of ...

HYDERABAD, Feb 3 (Reuters) - India's Divi's Laboratories (DIVI.NS), opens new tab reported a better-than-expected quarterly profit on Monday, aided by strong performance of its business that focuses ...

- Per. of shares (as a % of the total sh. of prom. and promoter group)----- - Per. of shares (as a % of the total Share Cap. of the company)----- Advisory Alert: It has come to our attention that ...